GSK : Très bon début d’année - guidance relevée
>T1 supérieur aux attentes - GSK publie un T1 au-dessus des attentes au niveau des ventes (+4.4% vs css) et de son core EPS (+15.9% vs css). Les ventes ressortent en hausse de 10% tcc (+6% GBP). Notons une bonne performance de toutes les divisions : Specialty Medicines (+12.8%, +1% vs css), Vaccines (+11.6%, +5.5% vs css) tirée par Arexvy (+180 M£ - lancé au T3 23, en ligne) et Shingrix (+13.4%, +4.4% vs css) General Medicine décline moins fortement qu’attendu (-4.4%,...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.